Head, Center of Excellence in Immunology
National Cancer Institute, NIH
Nicholas P. Restifo, MD is the Head of the Center of Excellence in Immunology, National Cancer Institute, NIH. He received his undergraduate degree with honors from The Johns Hopkins University and his medical degree from NYU. He performed post-doctoral training at Memorial Sloan Kettering Cancer Center and was recruited to the NCI in 1989.
Dr. Restifo has focused his entire scientific career on doing groundbreaking research on the curative role of T lymphocytes in the anti-tumor immune response. He built the first transgenic animal models showing that naturally-occurring T cells are able to reject every last cancer cell. He used these animal models to elucidate the principals of T cell-based cancer immunotherapy that were then used in human clinical trials. Dr. Restifo demonstrated that special class of stem cell-like T cells capable of eradicating cancer cells. Dr. Restifo is intimately involved in clinical trial activities using the adoptive transfer of large numbers of highly-reactive anti-tumor T lymphocytes. These clinical trials have recently had considerable success against a growing list human malignancies including melanoma, sarcoma, leukemia and lymphoma. Dr. Restifo has published more than 300 scientific papers and two dozen book chapters on cancer immunotherapy that have been cited more than 55,000 times according to Google Scholar. His work continues apace and within the past few years he has reported major findings in journals including Cell, Science and Nature. The data analytics firm Thomson Reuters has recently named him as one of the “World's most influential scientific minds.”
Saturday, June 17
10:00 AM – 10:30 AM
Academic Clinical Lecturer in Plastic Surgery
University of Oxford
Dr Fadi Issa is an NIHR Academic Clinical Lecturer in Plastic Surgery at the Nuffield Department of Surgical Sciences, University of Oxford, where he is a Principal Investigator at the Transplantation Research Immunology Group (TRIG). TRIG is a dynamic multidisciplinary international team of scientists and clinician scientists dedicated to the translation of research findings from the laboratory to the clinic with the ultimate aim of improving outcomes after transplantation. Dr Issa completed both his medical training and DPhil at the University of Oxford.
Saturday, June 17
10:30 AM – 11:00 AM
Chief, Division of Allergy and Immunology
Children's Research Institute
Catherine Bollard received her medical degree at the University of Otago in Dunedin, New Zealand. She is Board certified both in Pediatrics and Hematology. She worked both in New Zealand and London, England before moving to Baylor College of Medicine (BCM) in 2000 where she was Professor of Pediatrics, Medicine and Immunology and the Director of the Texas Children’s Cancer and Hematology Center Pediatric Lymphoma Program. In August 2013, she moved to Children’s National and The George Washington University School of Medicine and Health Sciences in Washington, DC. She is currently Chief, Division of Allergy and Immunology, Professor of Pediatrics and of Microbiology, Immunology and Tropical Medicine and Director of the Program for Cell Enhancement and Technologies for Immunotherapy (CETI). She is a member of the American Society for Clinical Investigation (ASCI) and is President of the International Society for Cellular Therapy (ISCT). She is on the Board of Directors of the Foundation for the Accreditation of Cellular Therapy (FACT) and Chairs the Non Hodgkins Lymphoma committee of the Children’s Oncology Group. She is an Associate Editor for the journals Blood and Cytotherapy and is a member of the NCI Clinical Oncology Study Section and is a member of the Cellular, Tissues and Gene Therapies Advisory Committee for the Food and Drug Administration (FDA). Her bench and translational research focuses on improving outcomes for patients after hematopoietic stem cell transplantation as well as the development of novel cell therapies for viral diseases and hematologic malignancies.
Saturday, June 17
11:00 AM – 11:30 AM